First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).-MedSci.cn

First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).

Bajorin, DF; Witjes, JA; Gschwend, J; Schenker, M; Valderrama, BP; Tomita, Y; Bamias, A; Lebret, T; Shariat, S; Park, SH; Ye, DW; Agerbaek, M; Collette, S; Unsal-Kacmaz, K; Zardavas, D; Koon, HB; Galsky, MD

JOURNAL OF CLINICAL ONCOLOGY, 2021; 39 (6):

科室
- - 订阅+
  - 更多科室
工具
服务